Alume Biosciences

Executive Summary

Alume Biosciences is a clinical-stage biotechnology company pioneering a novel nerve illumination technology to enhance surgical precision and patient outcomes. Its lead candidate, bevonescein (ALM-488), is a fluorescent peptide that binds to peripheral nerves, causing them to glow during surgery. This real-time visualization enables surgeons to identify and avoid critical nerve structures, thereby reducing the risk of nerve damage and associated complications such as paralysis, pain, or loss of function. Alume is initially targeting head-and-neck and prostate surgeries, where nerve injury is a frequent and debilitating consequence. The company is currently advancing bevonescein through Phase 3 clinical trials, positioning it for potential regulatory submission if successful. Alume's technology addresses a significant unmet need in surgery, where current nerve identification relies on electrical stimulation or anatomical knowledge, which can be unreliable. The company has demonstrated promising safety and efficacy in earlier trials, showing improved nerve preservation without adverse effects. With a strong intellectual property portfolio and a focus on high-value surgical markets, Alume is well-positioned to become a leader in intraoperative imaging. The upcoming Phase 3 data readouts and potential regulatory interactions represent critical inflection points, as positive results could lead to commercialization or a strategic partnership. The company continues to expand its pipeline and explore additional surgical indications beyond its initial focus.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 Data Readout for Head-and-Neck Surgery55% success
• Q2 2026Initiation of Phase 3 Trial for Prostate Surgery70% success
• Q3 2026FDA Type B Meeting or Breakthrough Therapy Designation50% success